Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Other financing activities (2022 - 2025)

Historic Other financing activities for Axsome Therapeutics (AXSM) over the last 4 years, with Q2 2025 value amounting to $3.2 million.

  • Axsome Therapeutics' Other financing activities rose 134222.22% to $3.2 million in Q2 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 71457.91%. This contributed to the annual value of $816000.0 for FY2024, which is 9479.19% down from last year.
  • Per Axsome Therapeutics' latest filing, its Other financing activities stood at $3.2 million for Q2 2025, which was up 134222.22% from $393000.0 recorded in Q1 2025.
  • In the past 5 years, Axsome Therapeutics' Other financing activities ranged from a high of $12.4 million in Q2 2023 and a low of $225000.0 during Q2 2024
  • For the 4-year period, Axsome Therapeutics' Other financing activities averaged around $2.8 million, with its median value being $1.2 million (2023).
  • In the last 5 years, Axsome Therapeutics' Other financing activities plummeted by 9818.62% in 2024 and then surged by 134222.22% in 2025.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Other financing activities stood at $5.2 million in 2022, then tumbled by 60.79% to $2.0 million in 2023, then crashed by 83.92% to $329000.0 in 2024, then soared by 886.32% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q2 2025, $393000.0 for Q1 2025, and $329000.0 during Q4 2024.